Analysts’ Weekly Ratings Updates for Relay Therapeutics (RLAY)

Several analysts have recently updated their ratings and price targets for Relay Therapeutics (NASDAQ: RLAY):

• 5/20/2026 – Relay Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/20/2026 – Relay Therapeutics had its price target raised by Barclays PLC from $21.00 to $27.00. They now have an “overweight” rating on the stock.
• 5/20/2026 – Relay Therapeutics had its price target raised by Citizens Jmp from $19.00 to $21.00. They now have a “market outperform” rating on the stock.
• 5/19/2026 – Relay Therapeutics was given a new $26.00 price target by UBS Group AG.
• 5/19/2026 – Relay Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc..
• 5/19/2026 – Relay Therapeutics was upgraded by JonesTrading from “hold” to “strong-buy”.
• 5/19/2026 – Relay Therapeutics had its price target raised by Raymond James Financial, Inc. from $23.00 to $26.00. They now have a “strong-buy” rating on the stock.
• 5/9/2026 – Relay Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/29/2026 – Relay Therapeutics had its price target raised by HC Wainwright from $19.00 to $25.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Relay Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $14.00 to $18.00. They now have an “outperform” rating on the stock.
• 4/28/2026 – Relay Therapeutics had its price target raised by Wells Fargo & Company from $17.00 to $21.00. They now have an “overweight” rating on the stock.
• 4/28/2026 – Relay Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $13.00 to $22.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Relay Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 4/28/2026 – Relay Therapeutics had its price target raised by Citizens Jmp from $17.00 to $19.00. They now have a “market outperform” rating on the stock.
• 4/14/2026 – Relay Therapeutics is now covered by JonesTrading. They set a “hold” rating and a $18.00 price target on the stock.
• 4/8/2026 – Relay Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/8/2026 – Relay Therapeutics had its price target raised by Barclays PLC from $17.00 to $21.00. They now have an “overweight” rating on the stock.
• 3/23/2026 – Relay Therapeutics had its price target raised by HC Wainwright from $14.00 to $19.00. They now have a “buy” rating on the stock.

Insider Transactions at Relay Therapeutics

In related news, CFO Thomas Catinazzo sold 17,717 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $12.86, for a total value of $227,840.62. Following the completion of the sale, the chief financial officer directly owned 195,178 shares of the company’s stock, valued at approximately $2,509,989.08. This represents a 8.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 40,449 shares of company stock valued at $532,889. Corporate insiders own 5.04% of the company’s stock.

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.